Fibroblast growth factor 21: a therapeutic target and diagnostic biomarker for early diagnosis of metabolic syndrome linked with neurodegenerative disorder

7th September 2022

Timing : 1 pm EST

Please use this zoom link for joining the webinar

Note: Registration is Required. Register here

For a list of all talks at the NanoBio seminar Series Fall'22, see here

In our earlier studies, we have established the link between metabolic syndrome (MetS) and neurodegenerative conditions, for which one of the major reasons might be the brain insulin resistance development (IR). Alzheimer's disease (AD) is a progressive neurodegenerative disorders without effective clinical cure. Exploring novel molecular targets and early diagnosis of these neurodegenartive disorders is an unmet needs clinically for effective management. Chronic stress during IR may influence the expression and release of Fibroblast growth factor 21 (FGF21), an endogenous hormone, known for its role to regulate glucose and energy metabolism in the body. Additionally, it has been discovered that diabetic and obese patients have an increased serum FGF21 levels during progression of MetS, which may be due to resistance development and or compensatory response to its receptor.